ViatrisHAM:VIA +0.06%60 FCF Yield % is 8.71 as of Jun. 27, 2026, which is 29% below its 10-year median of 12.29. GuruFocus rates HAM:VIA with a GF Score™ of 60/100 and a GF Value™ of €9.62 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Viatris ranks better than 85.17% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Viatris's Trailing 12-Month Free Cash Flow is €1,418 Mil, and Market Cap is €16,739 Mil. Therefore, Viatris's FCF Yield % for today is 8.71%.
The historical rank and industry rank for Viatris's FCF Yield % or its related term are showing as below:
HAM:VIA'
s FCF Yield % Range Over the Past 10 Years
Min: 3.44 Med: 12.29 Max: 28.7
Current: 8.71
During the past 13 years, the highest FCF Yield % of Viatris was 28.70%. The lowest was 3.44%. And the median was 12.29%.
HAM:VIA's FCF Yield % is ranked better than 85.17% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 0.67
vs HAM:VIA: 8.71
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Viatris FCF Yield % Related Terms
Viatris FCF Yield % Historical Data
* Premium members only.
The historical data trend for Viatris's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:VIA vs NBIX, UTHR, ELAN: FCF Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viatris FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viatris's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Viatris's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viatris (HAM:VIA) has a FCF Yield % of 8.71 as of Jun. 27, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Viatris and its competitors. This is 29% below median its historical median of 12.29. Over the past decade, Viatris' FCF Yield % has ranged from 3.44 to 28.70. According to the industry distribution chart, Viatris ranks #149 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 14.8%.
Is Viatris' FCF Yield % too high?
Viatris' current FCF Yield % of 8.71 is 29% below median its 10-year median of 12.29. Over the past 10 years, this metric has ranged from a low of 3.44 to a high of 28.70. The Drug Manufacturers industry median FCF Yield % is 0.67. Viatris' value of 8.71 is 1200% above this industry median. Based on the distribution chart, Viatris ranks #149 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Viatris has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viatris' FCF Yield % compare to NBIX and UTHR?
According to the Drug Manufacturers industry distribution chart, Viatris ranks #149 out of 1005 companies for FCF Yield %. This places Viatris in the top 15% of its industry — outperforming the majority of peers. The industry median FCF Yield % is 0.67. Viatris' value of 8.71 is 1200% above this benchmark. Historically, Viatris' own FCF Yield % has ranged from 3.44 to 28.70 over the past decade. While the company's 10-year median is 12.29 vs. the industry median of 0.67, Viatris has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.67, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viatris's current FCF Yield % of 8.71 is 1200% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Viatris and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viatris's current FCF Yield % is 8.71, which is 29% below median its own 10-year median of 12.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Based on GuruFocus' analysis, Viatris (HAM:VIA) is currently considered Significantly Overvalued. The stock's GF Value™ is €9.62, compared to a current price of €14.26 — trading 48.3% above its estimated fair value. The current FCF Yield % is 8.71, which is 29% below median its 10-year median of 12.29 and 1200% above the Drug Manufacturers industry median of 0.67. Viatris' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Viatris (HAM:VIA), the current FCF Yield % is 8.71 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viatris (HAM:VIA) Overvalued in 2026?
Based on GuruFocus' analysis, Viatris stock appears to be overvalued.
The current stock price of €14.26 is trading 48.3% above its estimated GF Value™ of €9.62.
GuruFocus considers Viatris to be Significantly Overvalued.
Key valuation signals for HAM:VIA:
FCF Yield %: 8.71 (29% below median its 10-year median of 12.29)
GF Value™: €9.62 vs. price of €14.26 (48.3% above fair value)
Industry Position: 1200% above the Drug Manufacturers median (#149 of 1005)
No single metric tells the full story. See the HAM:VIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
60GF Score
Get the complete analysis for HAM:VIA
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:VIA has been successfully added to your 
